A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INCB160058 When Administered Orally to Healthy Adult Participant
NCT ID: NCT06213818
Last Updated: 2025-10-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
137 participants
INTERVENTIONAL
2024-03-14
2025-08-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacodynamics, Safety and Pharmacokinetics After Oral Administration of BIBR 1048 MS in Healthy Volunteers
NCT02170116
A Study to Evaluate the Relative Bioavailability of New Formulations of INCB057643 Tablets Administered Orally in Healthy Participants
NCT06941077
Multiple Oral Doses of BIBR 1048 MS Solution in Healthy Volunteers
NCT02170831
Safety, Tolerability, Pharmacokinetics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers, Including Investigation of the Effect of Food on the Bioavailability of BI 1181181
NCT02044406
Safety, Tolerability, Pharmacokinetics and Early Pharmacodynamics of Single Rising Oral Doses of BI 1021958 Tablets in Healthy Male Volunteers
NCT01541488
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1: Dose
INCB160058 or placebo will be administered at protocol defined dose after an overnight fast.
INCB160058
Oral; Immediate release solid tablet
Placebo
Oral; Tablet
Cohort 2: Dose
INCB160058 or placebo will be administered at protocol defined dose after an overnight fast.
INCB160058
Oral; Immediate release solid tablet
Placebo
Oral; Tablet
Cohort 3: Dose
INCB160058 or placebo will be administered at protocol defined dose after an overnight fast.
INCB160058
Oral; Immediate release solid tablet
Placebo
Oral; Tablet
Cohort 4: Dose
INCB160058 or placebo will be administered at protocol defined dose after an overnight fast.
INCB160058
Oral; Immediate release solid tablet
Placebo
Oral; Tablet
Cohort 5: Dose
INCB160058 or placebo will be administered at protocol defined dose after an overnight fast.
INCB160058
Oral; Immediate release solid tablet
Placebo
Oral; Tablet
Cohort 6: Dose Treatment A
INCB160058 will be administered at protocol defined dose after an overnight fast.
INCB160058
Oral; Immediate release solid tablet
Cohort 6: Dose Treatment B
INCB160058 will be administered at protocol defined dose after a high-fat, high-calorie meal.
INCB160058
Oral; Immediate release solid tablet
Cohort 7: Dose
INCB160058 and esomeprazole will be administered at protocol defined schedule and dose.
INCB160058
Oral; Immediate release solid tablet
Esomeprazole
Oral; Delayed-release capsule or tablet
Cohort 8: Dose
INCB160058 will be administered at protocol defined dose after an overnight fast.
INCB160058
Oral; Immediate release solid tablet
Cohort 9: Dose
INCB160058 or placebo will be administered at protocol defined dose after an overnight fast.
INCB160058
Oral; Immediate release solid tablet
Placebo
Oral; Tablet
Cohort 10: Dose Treatment A
INCB160058 will be administered at protocol defined dose after an overnight fast.
INCB160058
Oral; Immediate release solid tablet
Cohort 10: Dose Treatment B
INCB160058 will be administered at protocol defined dose after a high-fat, high-calorie meal.
INCB160058
Oral; Immediate release solid tablet
Cohort 11: Dose
INCB160058 and esomeprazole will be administered at protocol defined schedule and dose.
INCB160058
Oral; Immediate release solid tablet
Esomeprazole
Oral; Delayed-release capsule or tablet
Cohort 12: Dose
INCB160058 and famotidine will be administered at protocol defined schedule and dose.
INCB160058
Oral; Immediate release solid tablet
Famotidine
Oral; Tablet
Cohort 13: Dose
INCB160058 or placebo will be administered at protocol defined dose after an overnight fast.
INCB160058
Oral; Immediate release solid tablet
Placebo
Oral; Tablet
Cohort 14: Dose
INCB160058 and famotidine will be administered at protocol defined schedule and dose.
INCB160058
Oral; Immediate release solid tablet
Famotidine
Oral; Tablet
Cohort 15: Dose
INCB160058 or placebo will be administered at protocol defined dose after an overnight fast.
INCB160058
Oral; Immediate release solid tablet
Placebo
Oral; Tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
INCB160058
Oral; Immediate release solid tablet
Placebo
Oral; Tablet
Esomeprazole
Oral; Delayed-release capsule or tablet
Famotidine
Oral; Tablet
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18 to 55 years, inclusive, at the time of signing the ICF.
* Body mass index between 18.0 and 32.0 kg/m2 (inclusive).
* Willingness to adhere to study-related prohibitions, restrictions, and procedures.
* Ability to swallow and retain oral medication.
* Willingness to avoid pregnancy or fathering children based on the criteria below.
* Male participants with reproductive potential must agree to use 1 of the highly effective methods of contraception to avoid fathering children from screening through the last follow-up visit and must refrain from donating sperm during this period. Permitted methods in preventing pregnancy should be communicated to the participants and their understanding confirmed.
* Female participants who are WOCBP must have a negative pregnancy test at screening and check-in, must agree to use 1 of the highly effective methods of contraception to avoid pregnancy from screening through the last follow-up visit, and must refrain from donating oocytes during this period.
Permitted methods in preventing pregnancy should be communicated to the participants and their understanding confirmed. Positive pregnancy tests may be confirmed at the investigator's discretion.
• Female participants not considered to be of childbearing potential are eligible and must have a negative pregnancy test at screening and check-in.
Exclusion Criteria
* History of rheumatologic/autoimmune disorders and immune deficiency/immunologic defects.
* Prior history of major bleeding or thrombosis, including myocardial infarction/stroke and pulmonary embolism/deep vein thrombosis.
* Known tuberculosis infection that is active or participant-reported history of tuberculosis or treatment thereof.
* Resting pulse \< 40 bpm or \> 100 bpm, confirmed by repeat testing at screening.
* History or presence of an abnormal ECG before initial dose administration that, in the investigator's opinion, is clinically significant (QTcF interval \> 450 milliseconds, QRS interval \> 120 milliseconds, and PR interval \> 220 milliseconds).
* Presence of a malabsorption syndrome possibly affecting drug absorption (eg, Crohn disease or chronic pancreatitis).
* Hemoglobin level, WBC count, platelet count, or absolute neutrophil count below the laboratory lower limit of normal at screening or at check-in, confirmed by repeat testing and clinically significant in the opinion of the investigator.
* Hepatic transaminase (ALT and AST), ALP, or total bilirubin levels \> 1.25 × the laboratory-defined ULN at screening or at check-in, confirmed by repeat testing (except participants with Gilbert disease, for which total bilirubin must be ≤ 2.0 × ULN).
* History of malignancy within 5 years of screening, with the exception of cured basal cell or squamous cell carcinoma of the skin, ductal carcinoma in situ, or prostate cancer.
* Current or recent (within 3 months of screening) clinically significant gastrointestinal disease or surgery (including cholecystectomy) that could affect the absorption of study drug, with the exception of appendectomy.
* Any major surgery within 12 weeks of screening.
* Donation of blood to a blood bank within 4 weeks of screening (within 2 weeks for plasma only).
* Blood transfusion within 4 weeks of check-in.
* Chronic or current active infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment.
* Positive test for hepatitis B virus, hepatitis C virus, or human immunodeficiency virus.
Note: Participants whose results are compatible with prior immunization or immunity due to infection for hepatitis B may be included at the discretion of the investigator.
* Regular alcohol consumption \> 21 units per week (1 unit = ½ pint beer or a 25-mL shot of 40% spirit, 1.5 to 2 units = 125-mL glass of wine, depending on type).
* Positive urine or breath test for ethanol or positive urine or serum screen for drugs of abuse that are not otherwise explained by permitted concomitant medications or diet.
* Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) before the first dose of study drug with another investigational medication or current enrollment in another investigational drug protocol.
* Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) before the first dose of study drug with an inducer or inhibitor of CYP3A4, P-gp, or BCRP (refer to the Drug Interaction Database for prohibited drugs).
* History of any significant drug allergy (such as anaphylaxis or hepatotoxicity) deemed clinically relevant by the investigator.
* Known hypersensitivity or severe reaction to INCB160058 or any excipients of INCB160058 (refer to the IB).
* Inability to undergo venipuncture or tolerate venous access.
* Inability or unlikeliness of the participant to comply with the dose schedule and study evaluations, in the opinion of the investigator.
* Use of tobacco- or nicotine-containing products within 1 month of screening.
* Use of prescription drugs (including oral, implantable, transdermal, injectable, intravaginal, or hormonal intrauterine contraceptives) or topical steroids within 14 days prior to study drug administration or nonprescription medications/products (including vitamins, minerals, and phytotherapeutic, herbal, or plant-derived preparations) within 7 days prior to study drug administration and during the study.
Note: Occasional use of acetaminophen (see Section 6.6.1) is permitted during the study.
* Women who are pregnant or breastfeeding.
* eGFR \< 90 mL/min/1.73 m2 based on the Chronic Kidney Disease Epidemiology Collaboration formula.
* Any history of hypersensitivity or intolerance to esomeprazole or any other PPI, or to famotidine or any other H2 antagonist.
* Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study treatment and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Incyte Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Incyte Medical
Role: STUDY_DIRECTOR
Incyte Corporation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nucleus Network Pty Ltd
Melbourne, Victoria, Australia
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INCB160058 When Administered Orally to Healthy Adult Participant
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
INCB160058-102
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.